Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05257083 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05257083 · ClinicalTrials.gov record · last posted 2026-03-17

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Study acronym: CARTITUDE-6
StatusActive, Not Recruiting
PhasePhase 3
Started2023-10-10
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.

Amendment record 27 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 27 times since 2022-02-16; most recent amendment 2026-03-15. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-09-11
Status change Recruiting→Active, Not Recruitingv25
2023-10-12
Status change Not Yet Recruiting→Recruitingv4
Trial Details
NCT Number NCT05257083
Lead Sponsor Stichting European Myeloma Network
Collaborators: Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 759 participants
Start Date 2023-10-10
Primary Completion 2033-06 (estimated)
Study Completion 2040-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-17